Aligos Therapeutics, Inc.
ALGS
$4.68
$0.112.41%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -74.60% | -63.40% | -53.82% | -1.90% | 11.66% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -74.60% | -63.40% | -53.82% | -1.90% | 11.66% |
| Cost of Revenue | -3.79% | 9.46% | 5.27% | -0.37% | -14.15% |
| Gross Profit | -15.33% | -31.78% | -23.95% | 0.00% | 19.19% |
| SG&A Expenses | -23.63% | -25.38% | -16.43% | -1.45% | 13.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.55% | -1.32% | -1.15% | -0.68% | -7.67% |
| Operating Income | -2.00% | -10.67% | -9.58% | 0.48% | 10.43% |
| Income Before Tax | -50.64% | 5.10% | 7.28% | -18.62% | 9.44% |
| Income Tax Expenses | -58.36% | -68.65% | -73.57% | 747.83% | 650.00% |
| Earnings from Continuing Operations | -49.65% | 5.78% | 7.92% | -19.43% | 8.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -49.65% | 5.78% | 7.92% | -19.43% | 8.71% |
| EBIT | -2.00% | -10.67% | -9.58% | 0.48% | 10.43% |
| EBITDA | -2.66% | -11.50% | -10.62% | -0.34% | 9.90% |
| EPS Basic | 47.85% | 71.84% | 56.90% | 33.64% | 28.72% |
| Normalized Basic EPS | 47.17% | 71.93% | 56.88% | 34.79% | 29.73% |
| EPS Diluted | 47.70% | 71.72% | 56.79% | 33.65% | 28.73% |
| Normalized Diluted EPS | 47.17% | 71.93% | 56.88% | 34.79% | 29.73% |
| Average Basic Shares Outstanding | 144.38% | 245.68% | 181.16% | 115.92% | 50.11% |
| Average Diluted Shares Outstanding | 144.46% | 245.79% | 181.28% | 115.92% | 50.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |